Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Epigenomics is Scopus-indexed (Q3, CiteScore 3.9), WoS SCIE. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1750-1911Verify ISSN ↗1750-192XVerify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 196 / 357 | 45th | Q3 |
| Cancer Research | 161 / 233 | 31st | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q3, CiteScore 3.9.
Epigenomics is Q3 in Genetics (rank 196 of 357) and Q3 in Cancer Research (rank 161 of 233), by CiteScore 2025.
Epigenomics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.9, which places it in quartile Q3 at the 45th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.774, quartile Q2, with an H-index of 85.
Epigenomics is published by Taylor and Francis Ltd. Its print ISSN is 1750-1911 and its online ISSN is 1750-192X.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Epigenomics has an h-index of 96 and a 2-year mean of 3.14 citations per paper (OpenAlex). Its Scopus CiteScore is 3.9, quartile Q3. On 2-year citations it ranks #129 of 353 Scopus journals in Genetics.
Epigenomics published 127 papers in 2025; its busiest recent year was 2020 with 160. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2025–2026), authors are most often from China (26.3%), United States (11.5%) and India (7.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (2 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.